Antithrombotic Management of Atrial Fibrillation in the Elderly

Medical Clinics of North America

Volumn 99, Issue 2, 2015, Pages 417-430

  Edholm, Karli ^a   Ragle, Nathan ^a   Rondina, Matthew T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Antiplatelet agents; Atrial fibrillation; Bleeding; Elderly; Risk stratification; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; IRBESARTAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; END STAGE RENAL DISEASE; FALL RISK; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEVERE RENAL IMPAIRMENT; AGED; ATRIAL FIBRILLATION; CAUSALITY; COMORBIDITY; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSALITY; COMORBIDITY; HUMANS; STROKE;

EID: 84925186216     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.11.012     Document Type: Review

References (51)

1. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. JAm Coll Cardiol 2014, 64(21):2246-2280.
2. Stroke Risk in Atrial Fibrillation Working Group Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69(6):546-554.
3. Brophy M.T., Snyder K.E., Gaehde S., et al. Anticoagulant use for atrial fibrillation in the elderly. JAm Geriatr Soc 2004, 52(7):1151-1156.
4. van Walraven C., Hart R.G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009, 40(4):1410-1416.
5. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
6. Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137(2):263-272.
7. Lopes R.D., Crowley M.J., Shah B.R., et al. Stroke prevention in atrial fibrillation 2013, Agency for Healthcare Research and Quality (US), Rockville (MD).
8. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28(2):125-136.
9. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33(21):2719-2747.
10. Jones C., Pollit V., Fitzmaurice D., et al. The management of atrial fibrillation: summary of updated NICE guidance. BMJ 2014, 348:g3655.
11. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
12. Olesen J.B., Fauchier L., Lane D.A., et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012, 141(1):147-153.
13. Olesen J.B., Torp-Pedersen C., Hansen M.L., et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012, 107(6):1172-1179.
14. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012, 33(12):1500-1510.
15. Singer D.E., Chang Y., Borowsky L.H., et al. Anew risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. JAm Heart Assoc 2013, 2(3):e000250.
16. Friberg L., Rosenqvist M., Lip G.Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation cohort study. Circulation 2012, 125(19):2298-2307.
17. Avgil Tsadok M., Jackevicius C.A., Rahme E., et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012, 307(18):1952-1958.
18. Pisters R., Lane D.A., Nieuwlaat R., et al. Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
19. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120(8):700-705.
20. Fang M.C., Go A.S., Chang Y., et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012, 43(7):1795-1799.
21. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867.
22. Ogilvie I.M., Newton N., Welner S.A., et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123(7):638-645.e4.
23. Waldo A.L., Becker R.C., Tapson V.F., et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. JAm Coll Cardiol 2005, 46(9):1729-1736.
24. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40(6):675-683.
25. Investigators A., Connolly S.J., Pogue J., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. NEngl J Med 2009, 360(20):2066-2078.
26. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364(9):806-817.
27. Donze J., Clair C., Hug B., et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012, 125(8):773-778.
28. Man-Son-Hing M., Nichol G., Lau A., et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159(7):677-685.
29. Tinetti M.E., Speechley M., Ginter S.F. Risk factors for falls among elderly persons living in the community. NEngl J Med 1988, 319(26):1701-1707.
30. Albrecht J.S., Liu X., Baumgarten M., et al. Benefits and risks of anticoagulation resumption following traumatic brain injury. JAMA Intern Med 2014, 174(8):1244-1251.
31. Singer D.E., Chang Y., Fang M.C., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151(5):297-305.
32. Olesen J.B., Lip G.Y., Lindhardsen J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011, 106(4):739-749.
33. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):546S-592S.
34. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(Suppl 2):e531S-e575S.
35. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370(9586):493-503.
36. Rash A., Downes T., Portner R., et al. Arandomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007, 36(2):151-156.
37. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S., Pogue J., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367(9526):1903-1912.
38. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361(12):1139-1151.
39. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365(10):883-891.
40. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365(11):981-992.
41. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2013, 369(22):2093-2104.
42. Dentali F., Riva N., Crowther M., et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012, 126(20):2381-2391.
43. Miller C.S., Grandi S.M., Shimony A., et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110(3):453-460.
44. Banerjee A., Lane D.A., Torp-Pedersen C., et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107(3):584-589.
45. Deedwania P.C. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med 2013, 126(4):289-296.
46. Sardar P., Chatterjee S., Chaudhari S., et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. JAm Geriatr Soc 2014, 62(5):857-864.
47. Goodman S.G., Wojdyla D.M., Piccini J.P., et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). JAm Coll Cardiol 2014, 63(9):891-900.
48. Halvorsen S., Atar D., Yang H., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014, 35(28):1864-1872.
49. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123(21):2363-2372.
50. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33(22):2821-2830.
51. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32(19):2387-2394.